Striatal dopamine D-2 receptors attenuate neuropathic hypersensitivity in the rat by Ansah, Osei B. et al.
05 (2007) 536–546
www.elsevier.com/locate/yexnrExperimental Neurology 2Striatal dopamine D2 receptors attenuate neuropathic hypersensitivity
in the rat
Osei B. Ansah a, Hugo Leite-Almeida a,b, Hong Wei a, Antti Pertovaara a,⁎
a Biomedicum Helsinki, Institute of Biomedicine/Physiology, POB 63, University of Helsinki, 00014 Helsinki, Finland
b Health and Life Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710 Braga, Portugal
Received 30 January 2007; revised 13 March 2007; accepted 15 March 2007
Available online 21 March 2007Abstract
Earlier studies indicate that striatal dopamine D2 receptors are involved in pain regulation in non-neuropathic conditions. We assessed whether
striatal dopamine D2 receptors contribute to pain regulation also in neuropathic conditions. The spared nerve injury model of neuropathy was
induced by unilateral ligation of the tibial and common peroneal nerves in the rat. In awake nerve-injured animals, pain-related withdrawal
responses to calibrated monofilaments or noxious heating were attenuated following striatal administration of a dopamine D2 receptor agonist
quinpirole. Pain-related responses were attenuated only in the nerve-injured limb ipsilateral to the injection and in the midline (tail). In unoperated
controls, striatal administration of quinpirole at an antihypersensitive dose did not influence withdrawal responses to mechanical stimulation.
Attenuation of pain-related responses induced by striatal administration of quinpirole was reversed by intrathecal administration of a dopamine D2
receptor antagonist (eticlopride) or a non-selective 5-HT receptor antagonist (methysergide), but not by an α2-adrenoceptor antagonist
(atipamezole). In the rostroventromedial medulla of lightly anesthetized neuropathic animals, striatal administration of quinpirole significantly
decreased the activity of presumably pronociceptive cells that are activated by noxious stimulation. The innocuous H-reflex in lightly anesthetized
control animals was not suppressed by striatal administration of quinpirole at an antihypersensitive dose. The results indicate that striatal dopamine
D2 receptors attenuate neuropathic hypersensitivity. The antihypersensitive effect induced by striatal dopamine D2 receptors in peripheral
neuropathy involves suppression of impulse discharge of presumably pronociceptive neurons in the rostroventromedial medulla, and a descending
influence acting on spinal 5-HT and dopamine D2 receptors.
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There is accumulating evidence indicating that the striatum,
the main input nucleus of the basal ganglia, might have a role in
pain processing (for reviews see Chudler and Dong, 1995;
Hagelberg et al., 2004; Neugebauer, 2006). This is indicated by
the findings that striatal neurons respond to noxious stimulation
in experimental animals (e.g., Chudler, 1998; Chudler et al.,
1993) and painful stimulation increases striatal blood flow in
human subjects (Casey et al., 1996; Coghill et al., 1999, 2002;
Derbyshire et al., 1997; Iadarola et al., 1998; Jones et al., 1991;
Svensson et al., 1997). Also, electrical stimulation of the⁎ Corresponding author. Fax: +358 9 191 25302.
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(Lineberry and Vierck, 1975). Although basal ganglia activation
by painful stimulation is often attributed to the inhibition or
preparation of motor activity, it has also been proposed to
represent an engagement of cerebral attentional systems during
sustained neuralgic pain (Downar et al., 2003). Dopaminergic
innervation of the striatum from the substantia nigra and striatal
dopamine D2 receptors appear to have an important role in
striatal processing of pain as indicated by the following findings.
Dopaminergic nigrostriatal neurons were found to be activated
by noxious stimulation (Schultz and Romo, 1987), lesions of
nigrostriatal neurons enhanced nociception (Carey, 1986; Lin et
al., 1981, 1984; Saade et al., 1997; Takeda et al., 2005) and
striatal administration of dopamine D2 receptor agonists
suppressed pain-related responses in experimental animals
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pain is a frequent symptom in degenerative diseases of the
nigrostriatal dopaminergic system such as Parkinson's disease
and burning mouth (Ford, 1998; Hagelberg et al., 2003b;
Jääskeläinen et al., 2001; Schott, 1985), patients with Parkin-
son's disease have lower pain thresholds than healthy controls
(Brefel-Courbon et al., 2005; Djaldetti et al., 2004), high
dopamine D2 receptor availability in the putamen is associated
with low pain sensitivity in healthy subjects (Hagelberg et al.,
2002; Pertovaara et al., 2004; Scott et al., 2006), and patients
with some chronic pain conditions exhibit higher dopamine D2
receptor availability in the putamen than their age- and sex-
matched controls (Hagelberg et al., 2003a,b).
Peripheral nerve injury may produce long-lasting neuropathic
pain and hypersensitivity. The maintenance of these nerve injury-
induced symptoms depends on abnormal discharge from
peripheral nerves (Devor, 2006) and pronociceptive changes in
the spinal segmental mechanismsmediating andmodulating pain-
related signals (Woolf and Salter, 2006). Additionally, changes in
descending pain modulation contribute to neuropathic symptoms
(Pertovaara, 2000; Porreca et al., 2002). Because the striatum
modulates spinal nociception (Belforte and Pazo, 2005) and
reflexes through the superior colliculus and the nucleus raphe
magnus (Basso and Evinger, 1996; Basso et al., 1996), we
propose a hypothesis that the striatum and its dopamine D2
receptors influence neuropathic symptoms by acting on the
brainstem–spinal pathways regulating nociception. To test this
hypothesis, we determined in animalswith the spared nerve injury
(SNI) model of neuropathy (Decosterd andWoolf, 2000) whether
striatal administration of a selective dopamineD2 receptor agonist
modulates pain-related behavior and/or the discharge rate of pain
regulatory neurons of the rostroventromedial medulla, a common
final pathway for descending influence (Gebhart, 2004).
Furthermore, various receptor antagonists were administered
intrathecally to assess the role of spinal neurotransmitters
involved in the possible modulation of pain-related behavior
induced by striatal dopamine D2 receptors.
Materials and methods
Animals and drugs
Adult male Hannover-Wistar rats (Harlan, Horst, The
Netherlands) weighing 200–300 g were used in this study.
They were kept in a room with a 12-h alternating light/dark
cycle and had access to food and water ad libitum. They were
also allowed some time (4–7 days) to get acclimatized to their
new environment in the laboratory prior to the start of
experiments. The study protocol was approved by the
Institutional Ethics Committee of the University of Helsinki
and the regional government of Southern Finland.
Surgical procedures for producing neuropathy
For inducing neuropathy, the spared nerve injury (SNI)
model, as described by Decosterd and Woolf (2000), was
adopted. Prior to surgery, the rat was anaesthetized with sodiumpentobarbital (OrionPharma, Espoo, Finland), administered
intraperitoneally at the dose of 60 mg/kg. An incision was
subsequently made into the skin on the lateral surface of the left
thigh, followed by a section through the biceps femoris muscle
to expose the sciatic nerve and its terminal branches: the sural,
common peroneal and tibial nerves. The common peroneal and
tibial nerves were then tightly ligated with 4–0 silk, sectioned
distal to the ligation and 3–4 mm of the distal nerve stump
removed. The sural nerve was left intact and care was exercised
not to stretch it.
Procedures for striatal and intrathecal microinjections
While the animals were under pentobarbital anesthesia and
secured in a stereotaxic frame, a 26-gauge stainless guide
cannula through which drugs could be delivered, was
unilaterally and chronically implanted in the dorsolateral
striatum (AP: 8.7 mm, ML: +4.2 mm, DV: −4.0 mm; Paxinos
and Watson, 1998) of the rat, for intrastriatal drug administra-
tions. Except for one group of rats, the guide cannula was
implanted on the side ipsilateral to the injured (SNI) limb (left
side) and anchored to the skull, using dental screw and cement.
A stainless dummy cannula was inserted into the guide cannula
to prevent blockage. This dummy cannula was always removed
during test-drug administration. A 10-μl Hamilton microsyringe
was connected to a 33-gauge stainless microinjection needle via
a 30–40 cm non-toxic polyethylene with an outer diameter of
0.61 mm (PE-10, Becton Dickinson & Co. USA) tubing.
Microinjection of drugs into the striatum was performed by
lowering this 33-gauge injection needle through the guide
cannula and delivering 0.5 μl of drug over a 10- to 30-s period.
The injection needle protruded about 1 mm beyond the tip of the
guide cannula. A deliberately trapped air bubble in the PE-10
tubing was used to monitor the flow of drug solution.
Intrathecal catheter was administered under pentobarbital
anesthesia using a method described by Størkson and colleagues
(1996). Briefly, a polyethylene (PE-10) tubing was inserted into
the lumbar subarachnoid space for intrathecal drug administra-
tions. The intrathecally inserted catheter was then fixed through
a layer of superficial muscles, tunneled rostrally and made to
appear through the skin in the occipital region. Upon recovery
from anesthesia, 10–15 μl of 2% lidocaine hydrochloride (Orion
Pharma), followed by 10–15 μl of saline was given through the
catheter – with the help of a 50-μl Hamilton microsyringe – to
verify if it was indeed intraspinally located. An immediate onset
of a temporal hind limb paralysis (lasting 15–30 min) was
considered to be indicative of correct intraspinal location of the
catheter. Only rats with catheters located intraspinally and with
no neurological deficits from the catheter were included in the
study. Test-drugs were injected intrathecally using a 50-μl
Hamilton microsyringe, flushed afterwards with saline.
Behavioral testing
Sensitivity to mechanical stimulation
Mechanical hypersensitivity of the lateral plantar surface of
the paw (sural nerve skin territory) was evaluated a day before
Table 1
Treatment groups in the behavioral study
Treatment group n Treatment received
Quin-3 7 Quinpirole 3 μg IC
Quin-10 22 Quinpirole 10 μg IC
Quin-20 8 Quinpirole 20 μg IC
Quin-30 9 Quinpirole 30 μg IC
Quin-10 contra 4 Quinpirole 10 μg IC contralaterally
Unoper-Quin-10 4 Unoperated control, Quinpirole 10 μg IC
Sal 6 Physiological saline IC
Quin-10 (Heat) 4 Quinpirole 10 μg IC (tail-flick and plantar heat tests)
Eti+Quin 4 Eticlopride 3 μg IT+Quinpirole 10 μg IC
Nal+Quin 3 Quinpirole 10 μg IC+Naloxone methiodide 10 μg IT
Met+Quin 5 Methysergide 10 μg IT+Quinpirole 10 μg IC
Ati+Quin 4 Atipamezole 5 μg IT+Quinpirole 10 μg IC
Eti IT 4 Eticlopride 3 μg IT
Nal IT 4 Naloxone methiodide 10 μg IT
Met IT 4 Methysergide 10 μg IT
Ati IT 4 Atipamezole 5 μg IT
Quin-30 IT 4 Quinpirole 30 μg IT
Quin-100 IT 13 Quinpirole 100 μg IT
IC=intracranial (intrastriatal); IT= intrathecal.
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Both the ipsi- and contralateral paws were studied. For this, the
rat was placed on an elevated wire grid and the lateral plantar
surface of the paw was stimulated with five different calibrated
von Frey monofilaments (North Coast Medical, Inc. Morgan
Hill, CA, USA) producing following forces: 1.4 g, 2 g, 6 g, 10 g
and 15 g. The monofilaments producing the lowest force should
produce a rather selective activation of mechanoreceptors, while
the monofilaments producing the highest force should activate
also a population of nociceptors (Leem et al., 1993). At each
particular time point studied, the paw ipsi- and contralateral to
the nerve injury was stimulated repeatedly for five times with
each of the five monofilaments applied at an ascending order.
For each monofilament, the number of brisk withdrawal
responses was recorded as a percentage of the five stimulations.
Mean of the five resulting percentages for each limb was
calculated and termed the pain score. Thus, if the animal
responded to every presentation of every monofilament, it got
the maximum pain score of 100.
Noxious heat-evoked responses
Radiant heat-induced limb withdrawal and tail-flick latencies
were used to assess thermal nociception. For the limb with-
drawal latency, Hargreaves' method (Hargreaves et al., 1988)
was employed, using a radiant heat equipment (Ugo Basile's
Plantar test model 7370, Comerio, Varese). For this, the rat was
placed on a glass plate and radiant heat applied to the plantar
surface of the hind paw from beneath, until spontaneous
withdrawal of the hind paw was achieved. An electronic counter
in the equipment registered the time in seconds from heat
application to limb withdrawal and this was considered as the
latency of limb withdrawal. The cut-off point was arbitrarily set
at 15 s after which time heat application was discontinued to
prevent possible tissue damage. For such a rat, the limb
withdrawal latency was recorded as 15 s. For the tail-flick
latency, radiant heat was applied to the tail, using a radiant heat
equipment (Socrel model DS-20, Ugo Basile, Comerio, Varese,
Italy). Time in seconds from the onset of tail heating to the first
reflex tail-flick was registered by the equipment and taken to be
the tail-flick latency. Ten seconds was arbitrarily set as the cut-
off point beyond which heating was discontinued to prevent
possible tissue damage. For both the limb withdrawal and tail-
flick latencies, time points studied were: pre-drug, 1, 5, 15 and
30 min post drug. At each time point, data were collected in
duplicate for the limb withdrawal and in triplicate for the tail-
flick, averaged and expressed as percentages of pre-drug values.
The minimum interval between successive heat stimulations of
the same skin site was one min.
Test drugs
The test drugs were (±)-quinpirole (a dopamine D2 receptor
agonist; Sigma-Aldrich Co. St. Louis MO, USA), S-(−) eticlo-
pride (a dopamine D2 receptor antagonist; Sigma), naloxone
methiodide (an opioid receptor antagonist that only poorly
spreads to the central nervous system following peripheral
administration; Sigma), methysergide maleate salt (a 5-HT
receptor antagonist that is not selective for 5-HT receptorssubtypes; Sigma), atipamezole (an α2-adrenoceptor antagonist
that is not selective for α2-adrenoceptor subtypes and that does
not bind to the 5-HT1A receptor, unlike many other α2-
adrenoceptor antagonists; OrionPharma, Espoo, Finland; Perto-
vaara et al., 2005), glutamate (Sigma), and saline placebo.
Course of the behavioral study
The test groups in the behavioral study are listed in
Table 1. When assessing pain-related behavior, the assessments
were performed before and at various time points following
injections of the test drugs. When attempting to reverse the
effects of striatal drug injections, various receptor antagonists
were administered intrathecally 15 min before the striatal
injection. Mechanical and heat sensitivity were determined in
separate sessions. Each animal participated in one to three
behavioral testing sessions and the interval between testing
sessions in the same animal was at least 2 days. Before using the
same animal again, the response to monofilaments was
determined to exclude any long-term effects by preceding drug
administrations. After the behavioral session, the animals
participated in a final electrophysiological session (see below).
Electrophysiological recordings of neurons in the
rostroventromedial medulla
To determine the potential role of various types of rostro-
ventromedial medullary (RVM) neurons to the antihypersensi-
tive effect induced by striatal quinpirole, the effect of striatal
drug injections on discharge rates of RVM neurons was
assessed. Recordings were performed only in animals with a
behaviorally verified neuropathy about 3–4 weeks following
the induction of SNI. Animals used in electrophysiological
recordings had participated in behavioral testing sessions 2–
5 days earlier (see above). At the beginning of the recording
session, anesthesia was induced by administering 60 mg/kg of
sodium pentobarbital i.p. Following induction of anesthesia, the
animal was placed in a standard stereotaxic frame according to
Table 2
The distribution of RVM neurons recorded following the administration of
quinpirole, glutamate or saline into the striatum ipsilateral to the nerve-injured
limb
Test drug Type of cell recorded Number of cells recorded
Quinpirole 10 μg On 22
Quinpirole 10 μg Off 15
Quinpirole 10 μg Neutral 10
Glutamate 50 nmol On 16
Glutamate 50 nmol Off 50
Physiological saline Off 13
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continued by administering sodium pentobarbital at the dose of
15–20 mg/kg/h. The level of anesthesia was frequently
monitored by assessing the size of the pupils, general muscle
tone and reflex responses to noxious pinching. Supplemental
doses of sodium pentobarbital were given as required. The rats
were spontaneously breathing and the body temperature was
maintained within a physiological range with a warming
blanket. The peripheral perfusion was checked by examining
the color of the ears and extremities.
With the rat secured in a stereotaxic frame, a hole was drilled
in the skull for placement of a stainless steel lacquer-coated
tungsten microelectrode (with tip impedance of 5–7 MΩ at
1 kHz) into the RVM (AP: −2.3 mm, ML: 0.0 mm, DV: 7.8–
9.8 mm; Paxinos and Watson, 1998). The signal was amplified
and filtered using standard techniques. Data sampling was
performed with a computer connected to a CED Micro 1401
interface and using Spike 2 software (Cambridge Electronic
Design, Cambridge, UK). Actual recordings did not start until
the animal was under light anesthesia; i.e., the animals gave a
brief withdrawal response to noxious pinch, but the pinch did not
produce any longer lasting motor activity, nor did the animals
have spontaneous limb movements. Before striatal drug
administrations, neurons were classified based on their response
to noxious pinch of the tail with a hemostatic clamp. This
stimulus was painful when applied to the finger of the
experimenters. Neurons giving excitatory responses to pinch
were considered ON-like ones, those giving inhibitory responses
were considered OFF-like neurons and neurons giving no or
only a negligible response to pinchwere considered NEUTRAL-
like neurons. In the present study, we defined that a pinch-
evoked change in the discharge rate had to be over 15% to be
considered as an excitatory or inhibitory response. Our
classification scheme of medullary neurons was modified from
that described by Fields and his co-workers (2006). Since we did
not verify whether pinch-evoked responses of RVM neurons
were associated with spinal reflex responses as in the original
classification scheme (Fields et al., 2006), we use the terms ON-
like or OFF-like neuron, instead of ON- or OFF-neuron. Our
previous results suggest, however, that there is practically no
difference in the classification of RVM neurons whether or not
spinal reflex responses are concurrently measured in lightly
anesthetized animals (Pertovaara et al., 2001).
After identification and classification of the RVM neuron, its
spontaneous activity was measured for 1–3 min. Then,
quinpirole (QUIN) at the dose 10 μg, glutamate (GLU) at the
dose of 50 nmol or physiological saline was injected into the
striatum. Neuronal discharge rate was then recorded up to
30 min post drug or saline administration. Table 2 shows the
distribution of cells recorded in different drug conditions. It
should be noted that in some cases it was possible to record
simultaneously more than one RVM neuron. In general,
quinpirole was injected once during the recording and glutamate
or saline injections were performed 1–3 times in the same
session at intervals of about an hour. In the final analysis, the
mean discharge rate following striatal injection of drug or saline
was compared in per cent with the corresponding meandischarge rate measured following the injection. In these
comparisons, the discharge rate 100% represents the discharge
rate prior to injection and a discharge rate >100% represents an
increase and a rate <100% a decrease in the discharge rate by
striatal injections. With quinpirole and saline, post-injection
discharge rate was measured 15 min following striatal
injections, while with glutamate injections post-injection
discharge rate was measured 1–3 min following striatal in-
jections. These time points were selected based on accompany-
ing behavioral findings and on pharmacokinetic properties of
drugs. These time points also proved to reflect maximum effects
induced by striatal injections in the present study. At the end of
the session, the animals were given a lethal dose of sodium
pentobarbital and the brains were removed. After fixing the
brains in 4% paraformaldehyde, they were sectioned with a
vibratome for verification of the recording and injection sites.
Representative slices were stained with formol–Thionin tech-
nique (Donovick, 1974).
Assessment of the innocuous H-reflex in control animals
To exclude the possibility that the attenuation of pain-related
responses by striatal quinpirole was due to suppression of
motor behavior, we determined the innocuous H-reflex in the
hind limb ipsilateral to the striatal injections. Due to SNI-
induced denervation of the hind limb, it was not possible to
determine the H-reflex in the neuropathic hind limb. Therefore,
the H-reflex was assessed in a group of unoperated control
animals using a technique that was slightly modified from that
described earlier (Gozariu et al., 1998). The reflex measure-
ments were performed under light sodium pentobarbital
anesthesia (25 mg/kg i.p. followed by supplemental adminis-
tration of 15–20 mg/kg/h). Needle electrodes were transcuta-
neously applied to the ankle of the hind limb for stimulation of
the tibial nerve (constant current 0.1 ms pulses of 0.5 Hz). The
amplitude of the tibial nerve stimulation was adjusted to give a
submaximal H-reflex response. A concentric bipolar electrode
was applied to the plantar muscles of the hind paw for
recording of electromyographic (EMG) response. In addition to
the monosynaptic H-reflex response, also the M-response
(caused by a direct activation of α-motoneurons and a
consequent activation of the effector muscle) was observed to
verify stability of the stimulation and recording conditions. The
amplitude of the H-reflex and M-response was determined by
averaging 10–20 consecutive responses to tibial nerve
stimulation prior to and 15 min after striatal administration of
saline (n=3) or quinpirole at the dose of 10 μg (n=4). Only one
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session, the animals were given a lethal dose of sodium
pentobarbital and the brains were removed for verification of
injection sites as described above.
Statistical analyses
Statistical analysis was performed using one-way or two-
way analysis of variance (ANOVA) followed by Tukey's test or
the Student's t-test (comparisons between two groups). Results
have been presented as mean±S.E.M. p<0.05 was considered
to represent a significant difference.
Results
Mechanical hypersensitivity and its attenuation by striatal
administration of quinpirole
By 2–4 weeks post surgery, rats with SNI had developed
marked hypersensitivity to innocuous mechanical stimulation of
the skin area innervated by the sural nerve ipsilateral to the SNI.
This is indicated by the finding that the pain scores to von Frey
hair stimulation of the lateral plantar surface of the paw were
significantly higher in the SNI than the unoperated group
(F1,47=20.9, p<0.0001; Fig. 1A). The pain scores wereFig. 1. Mechanical hypersensitivity assessed by determining a pain-related limb wi
contralateral to the spared nerve injury (SNI). (A) Baseline response without drug adm
unoperated controls. (B) Response of the neuropathic limb following administration o
rate of the neuropathic limb to various intensities of mechanical stimulation following
results for these same two groups are plotted as a total pain score in graph B. (D) Mec
striatum contralateral (Quin-contra) or ipsilateral (Quin-ipsi) to the nerve injury. Ipsi-
hypersensitivity following intrathecal administration of quinpirole. In each graph, p
represent no response. Sal=saline control. The error bars represent S.E.M. (In A, n=
*p<0.05 (t-test; reference: unless specified, the corresponding value in the SNI group
In B, D and E, *p<0.05, **p<0.01, ***p<0.005 (Tukey's test; reference: the corsignificantly different between the limbs (F1,47=7.5, p<0.01),
but this side-dependent difference was seen only in the SNI
group (F1,47=7.5, p<0.01). The pain score to stimulation of the
unoperated limb in the SNI group was not significantly higher
than the mean pain scores to stimulation of the limbs in the
unoperated group (Fig. 1A).
In the SNI group, administration of quinpirole, a dopamine
D2 receptor agonist, in the striatum ipsilateral to the nerve injury
effectively and dose-dependently attenuated mechanical hyper-
sensitivity (F4,47=3.6, p<0.02; Fig. 1B), while pain scores to
stimulation of the paw contralateral to the injury were not
changed (Fig. 1D). Of the doses studied, 10 and 20 μg proved to
be the most effective ones and their effects differed significantly
from that induced by saline control (Fig. 1B). The onset of the
attenuation of mechanical hypersensitivity occurred within
15 min (Fig. 2A). The antihypersensitive effect was sustained
for at least 2 h, but it had completely disappeared when the
animals were tested 1 or 2 days later (not shown). The pain
score used in the assessment of hypersensitivity consists of
withdrawal responses evoked by mechanical stimuli of varying
intensity. To determine whether the antihypersensitive effect
induced by striatal administration of quinpirole differentially
influences responses evoked by various intensities of mechan-
ical stimulation, we analyzed separately the frequency of thethdrawal response to repetitive mechanical stimulation of the hind paw ipsi- or
inistrations. Unoperated=withdrawal responses in the left and right hind limb of
f saline or quinpirole at various doses into the ipsilateral striatum. (C) Response
administration of saline or 10 μg of quinpirole into the ipsilateral striatum. The
hanical hypersensitivity following administration of 10 μg of quinpirole into the
limb=the neuropathic limb, Contra-limb=the contralateral limb. (E) Mechanical
ain score 100 represents the maximum pain-related response and pain score 0
22 in the SNI group and n=4 in the unoperated group; in B–E, n=4–13). In A
). In C, *p<0.05, **p<0.01 (t-test; reference: the corresponding saline group).
responding saline group).
Fig. 2. Mechanical antihypersensitive effect induced by striatal administration of quinpirole (Quin) at the dose of 10 μg (A) and its attempted reversal by
spinal administration of various receptor antagonists (B–C). Graph D shows the effect by intrathecal receptor antagonists alone. Sal=saline, Eti=3 μg of
eticlopride (a dopamine D2 receptor antagonist), Ati=5 μg of atipamezole (an α2-adrenoceptor antagonist), Nal=10 μg of naloxone methiodide (an opioid receptor
antagonist),Met=10 μg of methysergide (a 5-HT receptor antagonist). The error bars represent S.E.M. (n=4–22; see Table 1 for more details). *p<0.05, **p<0.01 (In
A and B, t-test; reference: the corresponding value in the Quin 10 μg-group. In C, Tukey's test. In D, t-test; reference: the corresponding pre-drug value).
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the five monofilaments to the neuropathic limb. The rate of
withdrawal responses was significantly increased with an
increase in stimulus intensity from 1.4 g to 15 g (F4,125=3.8,
p<0.01), and ipsilateral administration of quinpirole at the dose
of 10 μg into the striatum produced a significant decrease in the
rate of withdrawal responses (F1,125=27.1, p<0.0001), inde-
pendent of the stimulus intensity (F4,125=1.3; Fig. 1C).
Administration of 10 μg of quinpirole to the striatum
contralateral to the nerve injury had no effect on mechanical
hypersensitivity (Fig. 1D). In unoperated controls, striatal
administration of quinpirole at the dose of 10 μg had no effect
on responses to mechanical stimulation of the hind limb ipsi- or
contralateral to the striatal injection (n=4; not shown). Striatal
administration of quinpirole at the currently used doses did not
produce any marked change in behavior of neuropathic or
unoperated control animals, except for the antihypersensitive
effect in nerve-injured animals. Following intrathecal adminis-
tration, quinpirole produced a significant attenuation of
mechanical hypersensitivity at the dose of 100 μg but not at
the dose of 30 μg (Fig. 1E).
Spinal receptors involved in the antihypersensitive effect by
striatal administration of quinpirole
The attenuation of mechanical hypersensitivity induced
by striatal administration of quinpirole at the dose of 10 μg(Fig. 2A) was effectively blocked by intrathecal adminis-
tration of eticlopride, a dopamine D2 receptor antagonist, at
the dose of 3 μg (F1,111=27.06; p<0.0001; Fig. 2B).
Furthermore, the mechanical antihypersensitive effect
induced by striatal administration of quinpirole at the dose
of 10 g was reversed by intrathecal administration of 10 μg
of naloxone methiodide, an opioid receptor antagonist, or
10 μg of methysergide, a non-selective serotonin receptor
antagonist (Fig. 2C). In contrast, the mechanical antihyper-
sensitive effect induced by striatal quinpirole was not
reversed by intrathecal administration of 5 μg of atipame-
zole, an α2-adrenoceptor antagonist (Fig. 2C).
Intrathecal administrations of eticlopride, naloxone methio-
dide, atipamezole, or methysergide alone at the currently used
did not suppress mechanical hypersensitivity in the neuro-
pathic limb (Fig. 2D). Since the pain scores of the
neuropathic limb were close to the maximum value already
in the saline condition, it was not possible to assess reliably
whether spinally administered receptor antagonists alone
increased hypersensitivity in the neuropathic limb. Therefore,
the possible increase of hypersensitivity was assessed in the
limb contralateral to the nerve injury. While spinal adminis-
tration of atipamezole, eticlopride or methysergide alone did
not have a significant influence on pain scores in the
contralateral limb, naloxone methiodide alone produced a
significant increase in the pain scores of the contralateral limb
(Fig. 2D).
Fig. 3. Influence of striatal administration of quinpirole at the dose of 10 μg on
noxious heat-evoked paw flick (A) and tail flick (B) response in animals with a
spared nerve injury model of neuropathy. Quin-ipsi=withdrawal latency of the
neuropathic limb ipsilateral to the striatal injection of quinpirole, Quin-contra=
withdrawal latency of the limb contralateral to the nerve injury and striatal injection
of quinpirole. Sal-ipsi=withdrawal latency of the neuropathic limb ipsilateral to
the striatal injection of saline. Latency value 100% represents the corresponding
value prior to striatal injections and time point 0 min indicates when the striatal
injection was performed. The error bars represent S.E.M. (n=4 in each graph).
*p<0.05, **p<0.01 (Tukey's test; reference: the corresponding pre-injection
value), + (t-test; reference: the corresponding value in the saline group).
Fig. 4. Discharge rates of rostroventromedial medullary ON-, OFF- or
NEUTRAL-like neurons following striatal injections of 10 μg of quinpirole
(Quin), 50 nmol of glutamate (Glu) or saline (Sal). The discharge rate 100%
represents the corresponding discharge rate prior to striatal injection. The error
bars represent S.E.M. (n=10–50; see Table 2 for details). *p<0.05 (paired t-test;
reference: the corresponding discharge rate prior to striatal injection).
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Thermal nociception was studied only in the SNI group.
Before drug administration, radiant heat applied to the sural
nerve area in the hind paw induced a limb withdrawal at the
latency of 10.9±0.8 s (±S.E.M., n=4) in the injured side and
12.5±0.4 s in the contralateral side (p=0.05, paired t-test). The
mean radiant heat-induced tail-flick was induced at the latency
of 7.0±0.7 s (n=4). When compared with the effect of saline,
striatal administration of quinpirole at the dose of 10 μg
produced a significant prolongation of the radiant heat-induced
hind limb withdrawal latency (F3,48=9.77, p<0.0001; Fig.
3A). Post hoc testing indicated that the limb withdrawal latency
was increased only in the injured limb ipsilateral to the striatal
administration of quinpirole (Fig. 3A). The radiant heat-induced
tail-flick latency was increased following striatal administration
of quinpirole, too (F1,24=14.3; p<0.001; Fig. 3B).
Electrophysiological recordings
Effect of striatal microinjections of drugs on discharge rates of
rostroventromedial medullary neurons
To study potential role of rostroventromedial medullary
(RVM) neurons in mediation of the quinpirole-inducedantihypersensitive effect, we determined discharge rates of
various types of RVM neurons in neuropathic rats following
striatal administration of quinpirole at a dose (10 μg) that
produced a mechanical antihypersensitive and thermal anti-
nociceptive effect. Before striatal drug administrations, the
mean spontaneous discharge rate of ON-like neurons giving an
excitatory response to noxious peripheral stimulation was 8.1±
1.8 Hz (±S.E.M., n=22), that of OFF-like neurons giving an
inhibitory responses to noxious stimulation was 15.2±2.5 Hz
(n=15), and that of NEUTRAL-like neurons not responding to
peripheral noxious stimulation was 7.9±2 Hz (n=10). Quinpir-
ole produced a significant decrease in the baseline discharge
rate of ON-like neurons (n=22), whereas the effect of quin-
pirole was short of significance on baseline discharge rates of
OFF-like neurons (n=13) or NEUTRAL neurons (n=10; Fig.
4A). Striatal administration of glutamate at the dose of 50 nmol
had no significant effect on baseline discharge rates of ON-like
(n=16) or OFF-like (n=50) neurons, nor did saline influence
the baseline discharge rate of OFF-like neurons (n=13; Fig.
4B). Figs. 5 and 6 show the area of striatal microinjections and
the medullary region in which RVM neurons were recorded.
Effect of striatal quinpirole on the innocuous H-reflex
To study potential suppression of motor behavior as a cause
of antihypersensitive effect of striatal quinpirole, we assessed
the innocuous H-reflex in the hind limb of lightly anesthetized
animals. Since the SNI-induced denervation of the limb
Fig. 5. Photomicrographs showing a medullary recording site (upper graph) and
a striatal injection site (lower graph). The electrolytic lesion in the recording site
(upper graph) and the lesion in the striatal injection site (lower graph) are shown
by asterisks. In the lower graph, the lesion above the injection site indicates the
site of the guide cannula in the cortex. The upper and lower part of the brain
section shown in the lower graph were photographed separately and composed
digitally into one photomicrograph with Adobe Photoshop 7.0.1 software.
RMg=raphe magnus, RPa=raphe pallidus, py=pyramidal tract, Cx=cerebral
cortex, cc=corpus callosum, CPu=caudate–putamen. The calibration bar
represents 500 μm.
Fig. 6. (A) The extension of the striatal area in which the centers of
microinjections were in the behavioral and electrophysiological experiments.
CPu=caudate–putamen. (B) The extension of the medullary area in which
single-unit recordings were performed. RVM=rostroventromedial medulla.
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H-reflex was studied in an intact limb. Quinpirole at a dose of
10 μg or saline control did not suppress the amplitude of the
innocuous H-reflex in the hind limb ipsilateral to their striatal
administration (Fig. 7).
Discussion
The results indicate that striatal dopamine D2 receptors
attenuate pain-related responses in animals with peripheral
neuropathy. The attenuation of pain-related responses was
predominant in the neuropathic hind limb ipsilateral to the
striatal injection, although nociception in the midline (tail) was
also suppressed. The predominantly ipsilateral effect suggests
that involvement of a midline structure, such as the RVM, may
not alone explain the attenuation of a hypersensitive spinal
reflex response, but an ipsilateral relay in the brainstem, such asA11, is likely to contribute to the spinal antihypersensitive
effect (see further discussion below). The dose of a selective
dopamine D2 receptor agonist producing attenuation of
hypersensitivity in neuropathic animals was not sufficient to
reduce mechanical nociception in healthy control animals,
indicating enhanced antinociceptive efficacy of striatal D2
receptors in neuropathy. Interestingly, the dose–response curve
for the antihypersensitive effect of striatal quinpirole was U-
shaped. It should also be noted that since the striatal
microinjection of quinpirole at the volume of 0.5 μl is likely
to spread from the injection site to the adjacent cortical areas
(Myers, 1966), we cannot exclude a possible contribution of
cortical dopamine D2 receptors to the present findings.
The antihypersensitive effect induced by striatal administra-
tion of a dopamine D2 receptor agonist was not associated with
any other marked changes in behavior or with a suppression of
an innocuous H-reflex. It should be noted, however, that in this
study the H-reflex was assessed in an intact limb. Earlier studies
indicate that striatal stimulation could selectively suppress
nociceptive responses in the spinal trigeminal nucleus, without
an influence on the activity of trigeminal motoneurons (Belforte
and Pazo, 2005) and that striatal administration of a dopamine
D2 receptor agonist at an antinociceptive dose did not attenuate
motor behavior (Magnusson and Fisher, 2000). Although the
striatum is involved in motor control circuitries, the present and
earlier findings indicate that the striatum may also selectively
Fig. 7. (A) H-reflex and the M-response in the hind limb. The arrow indicates
time of stimulation. The curve shows an average response to 10 repetitive
stimuli. The horizontal calibration bar represent 4 ms and the vertical one 5 μV.
(B) Amplitude of the H-reflex following injection of saline or 10 μg of
quinpirole into the ipsilateral striatum. Amplitude value 100% represents the
corresponding value prior to striatal injection. The error bars represent S.E.M.
(n=3 in saline group and n=4 in quinpirole group).
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as control conditions.
Role of rostroventromedial medullary neurons in striatal
modulation of pain behavior
The rostroventromedial medulla (RVM) has an important role
in descending pain modulation, and it provides the final common
pathway for descending influence from various brain regions to
the spinal dorsal horn (Gebhart, 2004). Moreover, the RVM is
involved in relaying striatal influence on brainstem reflex blink
circuits through a pathway including the superior colliculus and
the raphemagnus nucleus in the RVM (Basso and Evinger, 1996).
In the present study, striatal activation of dopamine D2 receptors
attenuated the discharge rate of the ON cell-like RVM neurons.
Since ON-cells of the RVM have a pronociceptive role (Fields et
al., 2006), their decreased discharge rate might contribute to the
striatal dopamine D2 receptor-induced attenuation of pain-related
behavior in peripheral neuropathy. Increased discharge rate of
OFF cell-like RVM neurons that presumably have an antinoci-
ceptive role (Fields et al., 2006) was short of significance,
suggesting that the OFF-like neurons of the RVM had only a
minor contribution to the striatal dopamine D2 receptor-induced
suppression of pain behavior. NEUTRAL-cells of the RVM, that
have a less clear role in pain modulation (Fields et al., 2006), were
not influenced by striatal dopamine D2 receptors. Microinjection
of glutamate into the dorsal striatumdid not, unlike a dopamineD2
receptor agonist, produce significant changes in the discharge
rates of RVM cells. This finding suggests that the antinociceptiveefficacy of a striatal glutamate injection is lower than that of a
dopamine D2 receptor agonist. However, a recent study showed
that the antinociceptive effect of glutamate varies significantly
with the site of microinjection within the striatum (Belforte and
Pazo, 2005). The lack of glutamate effect in the present study
might be explained by a non-optimal dose or site of its admi-
nistration within the striatum.
Spinal neurotransmitter receptors involved in suppression of
pain-related behavior induced by striatal dopamine D2
receptors
The mechanical antihypersensitive effect induced by striatal
dopamine D2 receptors was reversed by spinal administration of
a dopamine D2 receptor antagonist, an opioid receptor antagonist
or a non-selective 5-HT receptor antagonist, but not by an α2-
adrenoceptor antagonist. The reversal of the antihypersensitive
effect by spinal administration of a dopamine D2 receptor
antagonist indicates that striatal dopamine D2 receptors activated
a dopaminergic nucleus with descending axonal projections
acting on spinal dopamine D2 receptors. This is in line with
previous results indicating that activation of the A11, a do-
paminergic brainstem nucleus, induces a spinal antinociceptive
effect due to action on spinal dopamine D2 receptors (Fleet-
wood-Walker et al., 1988) and that spinal administration of a
dopamine D2 receptor agonist has an antinociceptive action
(Jensen and Smith, 1982; Jensen and Yaksh, 1984; Tamae et al.,
2005). The present results indicate that the dose of the dopamine
D2 receptor agonist needed to attenuate neuropathic hypersensi-
tivity is an order of magnitude higher following spinal than
striatal administration.
The raphe magnus nucleus in the RVM provides a major
source of serotoninergic innervation to the spinal cord (Kwiat
and Basbaum, 1992). A number of previous studies have
demonstrated that raphe-spinal serotoninergic neurons are
involved in the modulation of pain-related responses (e.g.,
Rivot et al., 1984). It should be noted, however, that the pain
modulatory role of 5-HT appears to be complex and the
direction of its modulatory effect in the spinal dorsal horn is
influenced by many factors such as the type of 5-HT receptor
and the pathophysiological condition. Spinal 5-HT3 receptors
have a pronociceptive role in neuropathic animals (Suzuki et al.,
2004), whereas spinal 5-HT1A receptors predominantly suppress
pain-related responses in neuropathic and control conditions (el-
Yassir and Fleetwood-Walker, 1990; Lin et al., 1996; Liu et al.,
2002; Wei and Pertovaara, 2006). These previous results suggest
that the reversal of the antihypersensitive effect of striatal
dopamine D2 receptors by a non-selective 5-HT receptor
antagonist in the present study was predominantly due to the
blocking of raphe-spinal serotoninergic action on spinal 5-HT1A
receptors.
Endogenous opioids acting on spinal opioid receptors have
an important role in the regulation of spinal nociception (Fields
et al., 2006; Dickenson and Kieffer, 2006). In the present study,
spinal administration of an opioid receptor antagonist com-
pletely reversed the antihypersensitive effect induced by striatal
administration of a dopamine D2 receptor agonist. At the dose
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hypersensitivity. Therefore, opioid receptor antagonist-induced
reversal in the present study does not allow the conclusion that
spinal opioid receptors mediate the antihypersensitive effect of
striatal dopamine D2 receptors.
The attempt to reverse the antihypersensitive effect of striatal
dopamine D2 receptors by spinal administration of an α2-
adrenoceptor antagonist was short of significance. Thus, while
earlier studies indicate that the noradrenergic system has a
significant role in the feedback inhibition of sustained pain
(Pertovaara, 2006), the present findings suggest that descending
noradrenergic pathways do not play a critical role in striatal
modulation of hypersensitivity in the SNI model of neuropathy.
It should also be noted that striatal dopamine D2 receptors may
influence pain-related responses not only through descending
influence on sensory pathways, as in the present study, but
possibly also through supraspinal action on non-sensory factors.
For example, the association between striatal dopamine D2
binding and the subject's response criterion towards pain
suggests that modulation of motivational factors by striatal
dopamine D2 receptors may contribute to the subject's
experience of pain (Pertovaara et al., 2004).
Conclusions
In line with earlier results showing that striatal dopamine D2
receptors are involved in pain regulation in non-neuropathic
conditions (see Introduction for references), the present results
indicate that striatal dopamine D2 receptors influence pain-
related responses also in neuropathic conditions. The striatal
influence on neuropathic hypersensitivity involves suppression
of pronociceptive ON-like cells in the RVM, activation of
descending serotoninergic pathways acting on spinal 5-HT
receptors, and activation of descending dopaminergic pathways
acting on spinal dopamine D2 receptors. The involvement of
striatal dopamine D2 receptors in the regulation of neuropathic
hypersensitivity is in line with the hypothesis that a dysfunction
of the nigrostriatal dopaminergic system, such as in Parkinson's
disease, may increase pain sensitivity in patients with as well as
without peripheral neuropathy (Scherder et al., 2005; Wasner
and Deuschl, 2006).
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